bioRxiv Science⌕ Search

Biology subjects

Kiwanuka, M.

Publications and source records attributed to Kiwanuka, M..

2 recordsLinked to original sources

Volumetric mechanosensing of CAF in 3D hydrogels drive altered drug response in breast cancer

Altered mechanical properties of the tumor microenvironment (TME) influence cancer progression, yet the mechanistic basis by which 3D mechanics shape CAF heterogeneity and downstream tumor drug response remains poorly understood. Here, we engineered a modulus-tunable gelatin methacryloyl (GelMA) hydrogel platform spanning a normal-like (soft [~]2 kPa) to desmoplastic-like (stiff[~]40 kPa) range to culture primary breast CAFs under 3D confinement. CAFs exhibited pronounced volumetric morphoadaptation across matrices, with soft 3D matrices supporting larger, more protrusive morphologies and stiff gels constraining cell geometry. In contrast to canonical 2D paradigms, nuclear YAP localization was reduced in stiff 3D matrices and varied substantially across cells, consistent with a dominant role for 3D geometric/volumetric state in regulating mechanotransduction. Functionally, in transwell co-culture with MCF-7 spheroids under paclitaxel treatment, CAFs cultured in stiff 3D matrices induced a broader chemoresistance-associated transcriptional program, whereas soft 3D matrices CAFs favored stress/checkpoint-like responses. A 2D monolayer comparator indicated that coordinated resistance-associated programs emerge most clearly in 3D tumor architecture. Together, these results establish a GelMA-based biomaterials framework in which CAF volumetric state provides a quantifiable intermediate linking 3D matrix mechanics to mechanotransduction and tumor drug-response programs, motivating future strategies to modulate stromal function through mechanically controlled cell-state regulation.

bioengineering↗

Effect of paclitaxel treatment on cellular mechanics and morphology of human oesophageal squamous cell carcinoma of South African origin in 2D and 3D environments

During chemotherapy, structural and mechanical changes in malignant cells have been observed in several cancers, including leukaemia and pancreatic and prostate cancer. Such cellular changes may act as physical biomarkers for chemoresistance and cancer recurrence. This study aimed to determine how exposure to paclitaxel affects the intracellular stiffness of human oesophageal cancer of South African origin in vitro. A human oesophageal squamous cell carcinoma cell line WHCO1 was cultured on glass substrates (2D) and in collagen gels (3D) and exposed to paclitaxel for up to 48 hours. Cellular morphology and stiffness were assessed with confocal microscopy, visually aided morpho-phenotyping image recognition, and mitochondrial particle tracking microrheology at 24 and 48 hours. In the 2D environment, the intracellular stiffness was higher for the paclitaxel-treated than for untreated cells at 24 and 48 hours. In the 3D environment, the paclitaxel-treated cells were stiffer than the untreated cells at 24 hours, but no statistically significant differences in stiffness were observed at 48 hours. In 2D, paclitaxel-treated cells were significantly larger at 24 and 48 hours and more circular at 24 but not at 48 hours than the untreated controls. In 3D, there were no significant morphological differences between treated and untreated cells. The distribution of cell shapes was not statistically significant different across the different treatment conditions in 2D and 3D environments. Future studies with patient-derived primary cancer cells and prolonged drug exposure will help identify physical cellular biomarkers to detect chemoresistance onset and assess therapy effectiveness in oesophageal cancer patients. InsightMechanical changes in cancer cells by chemotherapeutic drugs exposure offer possible physical biomarkers for chemoresistance and cancer recurrence. This study on human oesophageal squamous cell carcinoma indicated that in vitro paclitaxel treatment induced stiffening and enlarging of malignant cells in two-dimensional environments at 24 and 48 hours. In physiologically more relevant three-dimensional collagen matrices the paclitaxel treatment led to cellular stiffening at 24 hours but softening thereafter, without significant changes in cellular size at any time. The outcomes need to be confirmed in future studies with prolonged drug exposure and patient-derived primary cancer cells.

cancer biology↗